Search

Displaying results 7321 - 7330 of 9714 in total
  1. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). … [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon.

  2. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

  3. Drug

    Dasatinib

    go.drugbank.com/drugs/DB01254
    ApprovedInvestigational

    [A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. … [A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  4. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor.

  5. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: Sunitinib 1A Pharma 12,5 mg - Hartkapseln, Sunitinib 1A Pharma 25 mg - Hartkapseln
  6. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing.

  7. Drug

    Hydralazine

    go.drugbank.com/drugs/DB01275
    ApprovedInvestigational

    Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. … [A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.

  8. Drug

    Pramlintide

    go.drugbank.com/drugs/DB01278
    ApprovedInvestigational

    It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. … Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals.

  9. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    Glisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake co...

  10. Drug

    Pirbuterol

    go.drugbank.com/drugs/DB01291
    ApprovedWithdrawn

    in a concentration between 10-50%. … Pirbuterol is a beta-2 adrenergic bronchodilator.

    Categories: Compounds used in a research, industrial, or household setting